HC Wainwright reaffirmed their buy rating on shares of Xeris Biopharma (NASDAQ:XERS – Free Report) in a report published on Thursday morning, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for Xeris Biopharma’s Q3 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.49 EPS.
Separately, Piper Sandler reiterated an overweight rating and issued a $3.00 price objective (down from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th.
Get Our Latest Stock Report on XERS
Xeris Biopharma Trading Up 2.7 %
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million for the quarter, compared to analysts’ expectations of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the prior year, the firm posted ($0.14) EPS. Analysts predict that Xeris Biopharma will post -0.4 EPS for the current year.
Institutional Investors Weigh In On Xeris Biopharma
Large investors have recently bought and sold shares of the stock. Simplicity Wealth LLC purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $27,000. Bayesian Capital Management LP acquired a new stake in shares of Xeris Biopharma during the 1st quarter worth about $37,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Xeris Biopharma by 4,512.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after buying an additional 15,929 shares in the last quarter. Quarry LP acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $47,000. Finally, Eagle Asset Management Inc. purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 42.75% of the company’s stock.
Xeris Biopharma Company Profile
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 8/12 – 8/16
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.